Document:

Exhibit 4.2 to Form S-8 for Matrix Bancorp, Inc.

                              MATRIX BANCORP, INC.

                      Amended and Restated Trust Under the
                      Executive Deferred Compensation Plan

                                  (Rabbi Trust)

                      AMENDED AND RESTATED TRUST UNDER THE
                     EXECUTIVE DEFERRED COMPENSATION PLAN OF

                              MATRIX BANCORP, INC.

         This  Agreement  is made by and  between  Matrix  Bancorp,  Inc.
("Company")  and  Matrix  Bancorp,  Inc. ("Trustee");

         WHEREAS, Company has adopted the Executive Deferred Compensation Plan
("Plan") as listed in Appendix A for the benefit of key employees and directors
of Company and its appointed subsidiaries ("Participating Subsidiaries");

         WHEREAS, Company has incurred or expects to incur liability under the
terms of such Plan with respect to the individuals participating in such Plan;

         WHEREAS, Company wishes to establish a trust (hereinafter called
"Trust") and to contribute to the Trust assets that shall be held therein,
subject to the claims of Company's creditors in the event of Company's
Insolvency, as herein defined, until paid to Plan participants and their
beneficiaries in such manner and at such times as specified in the Plan;

         WHEREAS, it is the intention of the parties that this Trust shall
constitute an unfunded arrangement for ERISA and shall not affect the status of
the Plan as an unfunded plan maintained for the purpose of providing deferred
compensation for a select group of management or highly compensated employees
for purposes of Title I of the Employee Retirement Income Security Act of 1974;

         WHEREAS, it is the intention of Company to make contributions to the
Trust equal to the amounts deferred pursuant to each respective Participant's
deferral elections to provide itself with a source of funds to assist it in the
meeting of its liabilities under the Plan;

         NOW, THEREFORE, the parties do hereby amend and restate their Trust
Agreement, dated December 7, 2000, and agree that the Trust shall be comprised,
held and disposed of as follows:

Section 1.        Establishment of Trust

         (a) Company hereby deposits with Trustee in trust a sum certain in
dollars to be determined at the time of deposit, which shall become the
principal of the Trust to be held, administered and disposed of by Trustee as
provided in this Trust Agreement.

         (b) The Trust hereby established is revocable by Company; it shall
become irrevocable upon a Change of Control, as defined herein.

         (c) The Trust is intended to be a grantor trust, of which Company is
the grantor, within the meaning of subpart E, part 1, subchapter J, chapter 1,
subtitle A of the Internal Revenue Code of 1986, as amended, and shall be
construed accordingly.

         (d) The principal of the Trust, and any earnings thereon, shall be held
separate and apart from other funds of Company and shall be used exclusively for
the uses and purposes of Plan participants and general creditors as herein set
forth. Plan participants and their beneficiaries shall have no preferred claim
on, or any beneficial ownership interest in, any assets of the Trust. Any rights
created under the Plan and this Trust Agreement shall be mere unsecured
contractual rights of Plan participants and their beneficiaries against Company.
Any assets held by the Trust will be subject to the claims of the general
creditors of Company and its Participating Subsidiaries under federal and state
law in the event of Insolvency, as defined in Section 3(a) herein.

         (e) Company, in its sole discretion, may at any time, or from time to
time, make additional deposits of cash or other property (including common stock
of the Company) in trust with Trustee to augment the principal to be held,
administered and disposed of by Trustee as provided in this Trust Agreement;
provided, however, in the event of a Change of Control, the Company shall as
soon as administratively possible, but in no event later than ten (10) days
following such event, make an irrevocable contribution to the Trust, in cash or
other marketable property, equal to the sum of (i) an amount which, when added
to the fair market value of the assets then held in the Trust, shall cause the
fair market value of the assets of the Trust to equal the present value of the
accrued benefits under the Plan as of the date of such Change of Control, and
(ii) an amount equal to a reasonable estimate of the present value of the
collective administrative, Trustee's, and legal fees to be incurred during the
life of the Trust on and after the Change of Control. Except in the event of a
Change of Control, neither Trustee nor any Plan participant or beneficiary shall
have any right to compel such additional deposits.

Section 2.        Payments to Plan Participants and Their Beneficiaries.

         (a) Company shall deliver to Trustee a schedule (the "Payment
Schedule") that indicates the amounts payable in respect of each Plan
participant (and his or her beneficiaries), that provides a formula or other
instructions acceptable to Trustee for determining the amounts so payable, the
form in which such amount is to be paid (as provided for or available under the
Plan), and the time of commencement for payment of such amounts. Except as
otherwise provided herein, Trustee shall make payments to the Plan Participants
and their beneficiaries in accordance with such Payment Schedule or other
instructions as provided. The Trustee shall make provision for the reporting and
withholding of any federal, state or local taxes that may be

required to be withheld with respect to the payment of benefits pursuant to the
terms of the Plan and shall pay amounts withheld to the appropriate taxing
authorities or determine that such amounts have been reported, withheld and paid
by Company.

         (b) The entitlement of a Plan participant or his or her beneficiaries
to benefits under the Plan shall be determined by Company or such party as it
shall designate under the Plan, and any claim for such benefits shall be
considered and reviewed under the procedures set out in the Plan.

         (c) Company may make payment of benefits directly to Plan participants
or their beneficiaries as they become due under the terms of the Plan. Company
shall notify Trustee of its decision to make payment of benefits directly prior
to the time amounts are payable to participants or their beneficiaries. In
addition, if the principal of the Trust, and any earnings thereon, are not
sufficient to make payments of benefits in accordance with the terms of the
Plan, Company shall make the balance of each such payment as it falls due.
Trustee shall notify Company where principal and earnings are not sufficient.

Section 3.        Trustee Responsibility Regarding Payments to Trust Beneficiary
                  When Company Is Insolvent.

         (a) Trustee shall cease payment of benefits to Plan participants and
their beneficiaries if the Company or a Participating Subsidiary is Insolvent.
Company or a Participating Subsidiary shall be considered "Insolvent" for
purposes of this Trust Agreement if (i) the entity is unable to pay its debts as
they become due, (ii) the entity is subject to a pending proceeding as a debtor
under the United States Bankruptcy Code, or (iii) the entity is determined to be
insolvent by a Federal or State Regulatory Banking Agency.

         (b) At all times during the continuance of this Trust, as provided in
Section l(d) hereof, the principal and income of the Trust shall be subject to
claims of general creditors of Company and its Participating Subsidiaries under
federal and state law as set forth below.

                  (1) The Board of Directors and the Chief Executive Officer of
         Company shall have the duty to inform Trustee in writing of the
         Insolvency of Company or a Participating Subsidiary. If a person
         claiming to be a general creditor of Company or Participating
         Subsidiary alleges in writing to Trustee that such entity has become
         Insolvent, Trustee shall determine whether such entity is Insolvent
         and, pending such determination, Trustee shall discontinue payment of
         benefits to Plan participants or their beneficiaries.

                  (2) Unless Trustee has actual knowledge of the Insolvency of
         the Company or a Participating Subsidiary, or has received notice from
         such entity (notice shall be made pursuant to paragraph 1 above) or a
         person claiming to be a creditor alleging that Company or Participating
         Subsidiary is Insolvent, Trustee shall have no duty to inquire as to
         the Insolvency of any such entity. Trustee may in all events rely on
         such evidence concerning Company's or a Participating Subsidiary's
         solvency as may be furnished to Trustee and that provides Trustee with
         a reasonable basis for making a determination concerning such entity's
         solvency.

                  (3) If at any time Trustee has determined that Company or a
         Participating Subsidiary is Insolvent, Trustee shall discontinue
         payments to Plan participants or their beneficiaries and shall hold the
         assets of the Trust for the benefit of such entity's general creditors.
         Nothing in this Trust Agreement shall in any way diminish any rights of
         Plan participants or their beneficiaries to pursue their rights as
         general creditors of such entity with respect to benefits due under the
         Plan or otherwise.

                  (4) Trustee shall resume the payment of benefits to Plan
         participants or their beneficiaries in accordance with Section 2 of
         this Trust Agreement only after Trustee has determined that Company or
         a Participating Subsidiary is not Insolvent (or is no longer
         Insolvent).

         (c) Provided that there are sufficient assets, if Trustee discontinues
the payment of benefits from the Trust pursuant to Section 3(b) hereof and
subsequently resumes such payments, the first payment following such
discontinuance shall include the aggregate amount of all payments due to Plan
participants or their beneficiaries under the terms of the Plan for the period
of such discontinuance, less the aggregate amount of any payments made to Plan
participants or their beneficiaries by Company in lieu of the payments provided
for hereunder during any such period of discontinuance.

Section 4.        Payments to Company.

         Except as provided in Section 3 hereof, after the Trust has become
irrevocable, Company shall have no right or power to direct Trustee to return to
Company or to divert to others any of the Trust assets before all payment of
benefits have been made to Plan participants and their beneficiaries pursuant to
the terms of the Plan.

Section 5.        Investment Authority.

         Trustee may invest and reinvest part or all of the assets of the Trust
in any real or personal property including, without limitation, investments in
any stock (including common stock of Company); debentures; mutual fund shares
(including shares with respect to which Trustee serves as a trustee, custodian
or investment advisor); notes; commercial paper; treasury bills; any common,
commingled or collective trust fund or pooled investment fund (including a fund
maintained by bank or trustee acting as Trustee); any interest bearing deposits
held by a bank or similar financial institution (including, to the extent
applicable, the Trustee); or any individual or group term, universal or other
life insurance policy. All rights associated with assets of the Trust shall be
exercised by Trustee or the person designated by Trustee, and shall in no event
be exercisable by or rest with Plan participants. The Company shall retain
authority and instruct Trustee regarding the investment and reinvestment of all
assets of the Trust.

Section 6.        Disposition of Income.

         During the term of this Trust, all income received by the Trust, net of
reasonable expenses and allocable taxes, shall be accumulated and reinvested.

Section 7.        Accounting by Trustee.

         Trustee shall keep accurate and detailed records of all investments,
receipts, disbursements, and all other transactions required to be made,
including such specific records as shall be agreed upon in writing between
Company and Trustee. Thirty (30) days following the close of each fiscal year
and within seven (7) days after the removal or resignation of Trustee, Trustee
shall deliver to Company a written account of its administration of the Trust
during such year or during the period from the close of the last preceding year
to the date of such removal or resignation, setting forth all investments,
receipts, disbursements and other transactions effected by it, including a
description of all securities and investments purchased and sold with the cost
or net proceeds of such purchases or sales (accrued interest paid or receivable
being shown separately), and showing all cash, securities and other property
held in the Trust at the end of such year or as of the date of such removal or
resignation, as the case may be. Upon the request of the Company, on a no more
than semi-annual basis, the trustee shall furnish the participant or the Company
an audit statement of the trust assets from an independent third party auditor.

Section 8.        Responsibility of Trustee.

         (a) Trustee shall act with the care, skill, prudence and diligence
under the circumstances then prevailing that a prudent person acting in like
capacity and familiar with such matters would use in the conduct of an
enterprise of a like character and with like aims, provided, however, that
Trustee shall incur no liability to any person for any action taken pursuant to
a direction, request or approval given by Company which is contemplated by, and
in conformity with, the terms of the Plan or this Trust and is given in writing
by Company. In the event of a dispute between Company and a party, Trustee may
apply to a court of competent jurisdiction to resolve the dispute.

         (b) If Trustee undertakes or defends any litigation arising in
connection with this Trust, Company agrees to indemnify Trustee against
Trustee's costs, expenses and liabilities (including, without limitation,
attorneys' fees and expenses) relating thereto and to be primarily liable for
such payments. If Company does not pay such costs, expenses and liabilities in a
reasonably timely manner, Trustee may obtain payment from the Trust.

         (c) Trustee may consult with legal counsel (who may also be counsel for
Company generally) with respect to any of its duties or obligations hereunder.

         (d) Trustee may hire agents, accountants, actuaries, investment
advisors, financial consultants or other professionals to assist it in
performing any of its duties or obligations hereunder, provided only that such
action shall be approved by Company in advance.

         (e) Trustee shall have, without exclusion, all powers conferred on
Trustees by applicable law, unless expressly provided otherwise herein,
provided, however, that if an insurance policy is held as an asset of the Trust,
Trustee shall have no power to name a beneficiary of the policy other than the
Trust, to assign the policy (as distinct from conversion of the policy to a
different form) other than to a successor Trustee, or to loan to any person the
proceeds of any borrowing against such policy.

         (f) Notwithstanding any powers granted to Trustee pursuant to this
Trust Agreement or to applicable law, Trustee shall not have any power that
could give this Trust the objective of

carrying on a business and dividing the gains therefrom, within the meaning of
section 301.7701-2 of the Procedure and Administrative Regulations promulgated
pursuant to the Internal Revenue Code.

Section 9.        Compensation and Expenses of Trustee.

         Company, in its discretion, may pay the administrative and Trustee's
fees and expenses. If not so paid, the fees and expenses shall be paid from the
Trust.

Section 10.       Resignation and Removal of Trustee.

         (a) Trustee may resign at any time by written notice to Company, which
shall be effective as agreed to by Trustee and Company but no later than thirty
(30) days after receipt of such notice.

         (b) Trustee may be removed by Company on three (3) days' notice or upon
shorter notice accepted by Trustee; provided, however, in the event of a Change
of Control, the Trustee may be removed solely by action of the Chief Executive
Officer of Company employed in that capacity immediately prior to such Change of
Control.

         (c) Upon resignation or removal of Trustee and appointment of a
successor Trustee, all assets shall subsequently be transferred to the successor
Trustee. The transfer shall be completed within fourteen (14) days after receipt
of notice of resignation, removal or transfer, unless Company extends the time
limit.

         (d) If Trustee resigns or is removed, a successor shall be appointed,
in accordance with Section 11 hereof, by the effective date of resignation or
removal under paragraph(s) (a) or (b) of this section. If no such appointment
has been made, Trustee may apply to a court of competent jurisdiction for
appointment of a successor or for instructions. All expenses of Trustee in
connection with the proceeding shall be allowed as administrative expenses of
the Trust.

Section 11.       Appointment of Successor.

         (a) If Trustee resigns or is removed in accordance with Section 10(a)
or (b) hereof, Company may appoint any third party, such as a bank trust
department or other party that may be granted corporate trustee powers under
state law, as a successor to replace Trustee upon resignation or removal. The
appointment shall be effective when accepted in writing by the new Trustee, who
shall have all of the rights and powers of the former Trustee. The former
Trustee shall execute any instrument necessary or reasonably requested by
Company or the successor Trustee to evidence the transfer.

         (b) The successor Trustee need not examine the records and acts of any
prior Trustee and may retain or dispose of existing Trust assets, subject to
Sections 7 and 8 hereof. The successor Trustee shall not be responsible for and
Company shall indemnify and defend the successor Trustee from any claim or
liability resulting from any action or inaction of any prior Trustee or from any
other past event, or any condition existing at the time it becomes successor
Trustee.

Section 12.       Amendment or Termination.

         (a) This Trust Agreement may be amended by a written instrument
executed by Trustee and Company. Notwithstanding the foregoing, no such
amendment shall conflict with the terms of the Plan or shall make the Trust
revocable after it has become irrevocable in accordance with Section l(b)
hereof.

         (b) The Trust shall not terminate until the date on which Plan
participants and their beneficiaries are no longer entitled to benefits pursuant
to the terms of the Plan unless sooner revoked in accordance with Section 1(b)
hereof. Upon termination of the Trust any assets remaining in the Trust shall be
returned to Company except that any assets (including shares of common stock of
Company) contributed to the Trust by Company for the benefit of participants of
a Participating Subsidiary shall revert to Company.

         (c) Upon written approval of participants or beneficiaries entitled to
payment of benefits pursuant to the terms of the Plan, Company may terminate
this Trust prior to the time all benefit payments under the Plan have been made.
All assets in the Trust at termination shall be returned to Company.

         (d) Sections 1 through 14 of this Trust Agreement may not be amended by
Company for two (2) years following a Change of Control, as defined herein.

Section 13.       Miscellaneous.

         (a) Any provision of this Trust Agreement prohibited by law shall be
ineffective to the extent of any such prohibition, without invalidating the
remaining provisions hereof.

         (b) Benefits payable to Plan participants and their beneficiaries under
this Trust agreement may not be anticipated, assigned (either at law or in
equity), alienated, pledged, encumbered or subjected to attachment, garnishment,
levy, execution or other legal or equitable process.

         (c) This Trust Agreement shall be governed by and construed in accordance
with the laws of Arizona.

         (d) For purposes of this Trust, Change of Control event shall mean any
of the following (other than as a result of a public offering of shares of the
Company):

          (i)  Any transaction (which shall include a series of transactions or
               a transaction occurring pursuant to a plan) that has the result
               that shareholders of the Company immediately before such
               transaction cease to own at least 51% of (x) the voting stock of
               the Company or (y) any entity that results from the participation
               of the Company in a reorganization, consolidation, merger,
               liquidation or any other form of corporate transaction;

          (ii) A merger, consolidation, reorganization, liquidation or
               dissolution in which the Company does not survive;

          (iii) A sale, lease, exchange or other disposition of all or
               substantially all of the property and assets of the Company; or

          (iv) The adoption of a resolution by the Board to the effect that any
               person or entity has acquired effective control of the business
               and affairs of the Company.

         Notwithstanding the foregoing, a Change of Control shall not be deemed
         to have occurred if there is consummated any transaction (or series of
         integrated transactions) immediately following which the record holders
         of the voting securities of the Company immediately prior to such
         transaction continue to have substantially the same proportionate
         ownership in the entity which owns all or substantially all of the
         assets of the Company immediately following such transaction

Section 14.       Effective Date.

         The effective date of this Amended and Restated Trust Agreement shall
be January 1, 2001.

         IN WITNESS WHEREOF, the undersigned have executed this Trust Agreement
by written consent this 11th day of May, 2001.

/s/ T. Allen McConnell                      /s/ Guy A. Gibson
For Matrix Bancorp, Inc.                    For Matrix Bancorp, Inc.
Title: Senior Vice President                Title:  President

                                   Appendix A

         The following nonqualified deferred compensation plan maintained by
Matrix Bancorp, Inc. is the object of the Trust Agreement to which this Appendix
A is attached:

o        The Matrix Bancorp, Inc. Executive Deferred Compensation Plan<PAGE>

     CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT
     HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. SECURITIES
     AND EXCHANGE COMMISSION

                                                                  Exhibit 10.121

                         AMENDMENT TO LICENSE AGREEMENT

     THIS AMENDMENT dated June 22, 2001 (this "Amendment"), to the License
Agreement (the "Agreement") dated December 23, 1999, between Interneuron
Pharmaceuticals, Inc.("Interneuron") and Warner-Lambert Company ("Warner")
related to the development and commercialization of the pharmaceutical compound
known as pagoclone.

                                    RECITALS

A.   The Agreement provides that Warner shall either achieve certain steps in
     clinical development of the Product by specified dates or, in the event of
     its failure to achieve such steps, make certain payments to Interneuron,
     and also provides that Warner shall make specified payments to Interneuron
     upon the achievement of particular development milestones; and

B.   Warner and Interneuron wish to amend the Agreement as it relates the date
     and payment concerning the commencement of Phase III clinical trials for
     General Anxiety Disorder.

     THEREFORE, for good and valuable consideration, the receipt and sufficiency
     of which is hereby acknowledged, Warner and Interneuron hereby agree as
     follows:

     1. Except as may be specifically defined herein, any term used as a defined
        term in this Amendment shall have the meaning as defined in the
        Agreement.

     2. Section 3.7 (b)(3) of the Agreement is amended in its entirety to
        provide as follows:

                  "3. Either dose the first patient in a Phase III Clinical
                  Trial for General Anxiety Disorder by the 30 month anniversary
                  of the date that this Agreement is fully signed by authorized
                  representatives of each party, or pay to Interneuron the
                  amount set forth in Section 4.2(a)(2) (which payment shall be
                  deemed to be in lieu of the obligation to make such payment
                  under Section 4.2(a)) less any amounts paid under Section
                  3.7(b)(2) above; provided, however, that if Warner shall be
                  unable to conduct such Phase III Clinical Trial for General
                  Anxiety Disorder due to action on the part of the FDA or any
                  foreign equivalent, including, without limitation, the
                  placement of a clinical hold on such clinical trial, then
                  (except in a case where such circumstance is directly caused
                  by any negligent act or omission of Warner) the aforementioned
                  30 month anniversary shall be extended by a period of time
                  equal to the period during which Warner shall be unable to
                  conduct such trial due to such action on the part of the FDA
                  or any foreign equivalent."

<PAGE>

                                                                     Page 2 of 3

     3.  Section 3.7 (c) is deleted from the Agreement.

     4.  Section 4.2 (a)(2) of the Agreement is amended by changing the term "$
         [*]" to the term "$ [*]".

     5.  Article 8 of the Agreement is amended by adding thereto a new Section
         8.6 providing as follows:

         "8.6 Termination by Warner Before 30 Month Anniversary of the
         Agreement. Notwithstanding any term or provision of this Agreement,
         including, without limitation, Section 3.7(b)(3), the first sentence of
         Section 8.1, Section 8.3 and the first sentence of Section 8.5, if
         Warner shall give notice of exercise of its right to terminate this
         Agreement under Section 8.1 or under the first sentence of Section 8.3
         hereof on or before the 30 month anniversary of the date that this
         Agreement is fully signed by authorized representatives of each party
         (or, if applicable, on or before the date to which such 30 month
         anniversary shall be extended pursuant to Section 3.7(b)(3)), and at
         the time of the giving of such notice Warner shall not have dosed the
         first patient in a Phase III Clinical Trial for General Anxiety
         Disorder, then Warner shall nevertheless not be obliged to make the
         payment provided for in Section 3.7 (b)(3) hereof, notwithstanding the
         circumstance that this Agreement may remain in effect for a period
         after such anniversary (or, for a period after the date to which such
         anniversary may be so extended) (i) due to the operation of the six
         month notice provision contained in Section 8. 1, or (ii) due to the
         operation of the provisions of Section 8.3 that give the Breaching
         Party a right to cure a material breach hereof, provided, however, that
         if the Breaching Party shall cure such breach in compliance with the
         provisions of Section 8.3, and as a result of such cure this Agreement
         shall continue in effect after such thirty month anniversary (or after
         such date to which such anniversary may be so extended) then, subject
         to the terms hereof, Warner shall be obliged to make such payment
         provided for under Section 3.7 (b)(3)."

*Confidential Treatment Requested.

<PAGE>

                                                                     Page 3 of 3

     6.  Except as amended by this Amendment, the Agreement, including, without
         limitation'. Article 8 thereof, shall remain in full force and effect.

         IN WITNESS WHEREOF, Warner and Interneuron have executed this Amendment
to License Agreement in duplicate originals by their proper officers.

INTERNEURON PHARMACEUTICALS, INC. WARNER-LAMBERT COMPANY

By /s/ Mark Butler                           By /s/ Alan Weiner
   ---------------------------                  ------------------------
 Title: EVP                                     Title:  Vice President

Date:  6/21/01                               Date: 6/22/01
       ---------------                             ---------------------

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00032-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00032-of-00352.parquet"}]]